TY - JOUR
T1 - Epidemiology of infectious complications in cancer patients.
AU - Zembower, T.
N1 - Copyright:
This record is sourced from MEDLINE/PubMed, a database of the U.S. National Library of Medicine
PY - 1998
Y1 - 1998
N2 - Patients with underlying malignancies are at risk for a wide array of infectious diseases that cause significant morbidity and mortality. To develop a clear etiologic understanding of the infectious agents involved first requires a knowledge of the factors that predispose to infection. Neutropenia is clearly the single most important risk factor for infection in the cancer patient. However, a variety of both host and treatment-associated factors act together to predispose these patients to opportunistic infections. Approaching the individual malignancies with a knowledge of the underlying risk factors helps logically guide diagnosis and therapy. The astute clinician must also be aware of new and emerging infections in this patient population. As new pathogens are discovered and established pathogens become increasingly drug resistant, they will continue to present challenges for physicians caring for these patients in the years ahead.
AB - Patients with underlying malignancies are at risk for a wide array of infectious diseases that cause significant morbidity and mortality. To develop a clear etiologic understanding of the infectious agents involved first requires a knowledge of the factors that predispose to infection. Neutropenia is clearly the single most important risk factor for infection in the cancer patient. However, a variety of both host and treatment-associated factors act together to predispose these patients to opportunistic infections. Approaching the individual malignancies with a knowledge of the underlying risk factors helps logically guide diagnosis and therapy. The astute clinician must also be aware of new and emerging infections in this patient population. As new pathogens are discovered and established pathogens become increasingly drug resistant, they will continue to present challenges for physicians caring for these patients in the years ahead.
UR - http://www.scopus.com/inward/record.url?scp=0031609581&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031609581&partnerID=8YFLogxK
U2 - 10.1007/978-0-585-38152-7_2
DO - 10.1007/978-0-585-38152-7_2
M3 - Review article
C2 - 9711395
AN - SCOPUS:0031609581
SN - 0927-3042
VL - 96
SP - 33
EP - 75
JO - Cancer treatment and research
JF - Cancer treatment and research
ER -